Inhibition of NRF1/ABCC1 improves chemosensitivity of human lung adenocarcinoma cell lines to cisplatin

doi:10.16352/j.issn.1001-6325.2025.01.0051

Abstract

Abstract: Objective To explore the effect of nuclear respiratory factor 1(NRF1) activation of ATP binding cassette transporter C1(ABCC1) transcription on cisplatin resistance in lung adenocarcinoma cells and its potential mechanisms. Methods The expression levels of ABCC1 in lung adenocarcinoma tumor tissues were analyzed by oncogenomic datasets. Cells were grouped into: sh-NC, sh-ABCC1, sh-NC+oe-NC, sh-NRF1+oe-NC and sh-NRF1+oe-ABCC1. Real-time polymerase chain reaction (RT-qPCR) was used to detect the expression of ABCC1 in lung adenocarcinoma cells. Cisplatin-resistant lung adenocarcinoma cell strains were constructed to detect the expression level of ABCC1. Cell proliferation, migration and invasion were assessed by colony formation and Transwell assay. The IC₅₀ values of drug-resistant lung adenocarcinoma cells treated with different doses(0, 0.001, 0.002,0.004, 0.008,0.016 and 0.032 mg/mL) of cisplatin were detected by CCK-8 assay. Western blot was used to detect the protein expression of epithelial-mesenchymal transition markers (E-cadherin, N-cadherin). Dual luciferase and ChIP assays were performed to verify the binding relationship between NRF1 and ABCC1. Results ABCC1 was highly expressed in lung adenocarcinoma tumor tissues and cells. Compared with cisplatin-sensitive lung adenocarcinoma cells, ABCC1 was highly expressed in cisplatin-resistant lung adenocarcinoma cells, and knockdown of ABCC1 significantly inhibited cell proliferation, migration and invasion, and increased the expression of E-cadherin (P＜0.05) and decreased the expression of N-cadherin (P＜0.05). Knockdown of ABCC1 significantly increased the sensitivity of lung adenocarcinoma cells to cisplatin (P＜0.05). In addition, dual luciferase and ChIP experiments confirmed the binding relationship between NRF1 and ABCC1 promoter de-binding, and NRF1 could activate the transcription of ABCC1. Knockdown of NRF1 attenuated the inhibitory effect of over-expressed ABCC1 on the proliferation, migration, invasion and cisplatin-resistance of lung adenocarcinoma cells(P＜0.05). Conclusions This study revealed the effect of the NRF1/ABCC1 axis enhancement is a potential strategy to overcome the barrier of cisplatin-resistance in chemotherapy of lung adenocarcinoma.

Key words: nuclear respiratory factor 1(NRF1), ATP binding cassette transporter C1(ABCC1), lung adenocarcinoma, epithelial-mesenchymal transition, chemotherapy resistance

CLC Number:

R734.2

CHEN Qingxia, LIANG Yuling, LUO Yalan, NIU Bin. Inhibition of NRF1/ABCC1 improves chemosensitivity of human lung adenocarcinoma cell lines to cisplatin[J]. Basic & Clinical Medicine, 2025, 45(1): 51-59.

References

[1] Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018,9:117. doi:10.1038/s41419-017-0063-y.
[2] Sato C, Okuda K, Tamiya H, et al. Acute arterial thrombosis during postoperative adjuvant cisplatin-based chemotherapy for completely resected lung adenocarcinoma[J]. Intern Med, 2018,57:557-561. doi:10.2169/internalmedicine.8996-1.
[3] Wang Q, Cheng N, Li X, et al. Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma[J]. Oncotarget, 2017,8:2558-2567. doi:10.18632/oncotarget.13708.
[4] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54:95-117. doi:10.1146/annurev-pharmtox-011613-135959.
[5] Rice AJ, Alvarez FJ, Davidson AL, et al. Effects of lipid environment on the conformational changes of an ABC importer[J]. Channels (Austin),2014,8:327-333. doi:10.4161/chan.29294.
[6] Liu L, Zhang Q, Peng H. Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer[J]. J Chemother, 2023,35:39-52. doi:10.1080/1120009X.2022.2043515.
[7] Li Z, Li S, Wen Y,et al. MiR-495 inhibits cisplatin resistance and angiogenesis in esophageal cancer by Targeting ATP7A[J]. Technol Cancer Res Treat, 2021,20:15330338211039127. doi:10.1177/15330338211039127.
[8] Zhao X, Li X, Zhou L, et al. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3[J]. Cancer Sci, 2018,109:3068-3079. doi:10.1111/cas.13764.
[9] Cao Y, Xie X, Li M, et al. CircHIPK2 Contributes to DDP resistance and malignant behaviors of DDP-resistant ovarian cancer cells both in vitro and in vivo through circHIPK2/miR-338-3p/CHTOP ceRNA pathway[J]. Onco Targets Ther, 2021, 14:3151-3165. doi:10.2147/OTT.S291823.
[10] Adamska A, Falasca M. ATP-binding cassette transpor-ters in progression and clinical outcome of pancreatic cancer: What is the way forward[J]. World J Gastroenterol, 2018, 24:3222-3238. doi:10.3748/wjg.v24.i29.3222.
[11] Huang C, Qin L, Chen S, et al. CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression[J]. Anticancer Drugs, 2023, 34:395-404. doi:10.1097/CAD.0000000000001465.
[12] Wang X, Wang H, Jiang H, et al. Circular RNAcirc_0076305 promotes cisplatin (DDP) resistance of non-small cell lung cancer cells by regulating ABCC1 through miR-186-5p[J]. Cancer Biother Radiopharm, 2023, 38:293-304. doi:10.1089/cbr.2020.4153.
[13] Zheng F, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis[J]. Biomed Pharmacother, 2020, 124:109828. doi:10.1016/j.biopha.2020.109828.
[14] Zhou Y, Xu Z, Quan D, et al. Nuclear respiratory factor 1 promotes spheroid survival and mesenchymal transition in mammary epithelial cells[J]. Oncogene, 2018, 37:6152-6165. doi:10.1038/s41388-018-0349-2.
[15] Liu X, Chen J, Zhang S, et al. LINC00839 promotes colorectal cancer progression by recruiting RUVBL1/Tip60 complexes to activate NRF1[J]. EMBO Rep, 2022, 23:e54128. doi:10.15252/embr.202154128.